Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro

Friday, November 15, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising effects of capsid assembly modulators, particularly ALG-001075, in inducing significant HBV DNA knockdown and directly targeting HBeAg in vitro. These findings suggest potential advancements in the treatment of chronic HBV infection. The research highlights the importance of continued exploration in this area.
Price reaction · baseline $19.46 (2024-11-14 close) · hit pre-market · 3 other ALGS headline(s) in the window, move may be shared
day 0 close
-1.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Capsid assembly modulators like ALG-001075 show promising results.
  • Significant HBV DNA knockdown observed in vitro.
  • Direct targeting of HBeAg indicates potential for effective treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-001075?

ALG-001075 is a capsid assembly modulator that targets HBV.

How does ALG-001075 affect HBV DNA?

It induces significant HBV DNA knockdown in vitro.

What is the significance of targeting HBeAg?

Targeting HBeAg may enhance treatment effectiveness for HBV.

What are capsid assembly modulators?

They are compounds that disrupt the assembly of viral capsids.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-001075 HBV HBeAg chronic HBV infection biopharma
Last updated: Nov 15, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →